Lupin Ltd., (NSE: LUPIN) announced that the U.S. FDA has approved Ranluspec (ranibizumab-hkdz), its interchangeable biosimilar to Lucentis (Genentech). The approval covers both vial and pre-filled syringe formats in the same strengths as Lucentis, 0.3 mg and 0.5 mg.
Ranluspec is a recombinant humanized monoclonal antibody fragment that blocks vascular endothelial growth factor A. It is indicated for several vision-threatening conditions, including wet-age related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
Company executives highlighted the milestone as Lupin's second U.S. biosimilar approval, underscoring its growing biologics portfolio. CEO Vinita Gupta said the launch expands patients' access to proven vision therapies, while Managing Director Nilesh Gupta emphasized the company's manufacturing capabilities and commitment to affordable treatments.
Dr. Cyrus Karkaria, President of Biotechnology at Lupin, added that the FDA nod reinforces Lupin's expertise in biologics development and its mission to broaden access to advanced therapies worldwide.
Headquartered in Mumbai, Lupin operates across more than 100 markets, with strengths in branded and generic formulations, complex generics, biotechnology, and APIs. The company runs 15 manufacturing sites and seven research centers globally, supported by over 24,000 employees.
Lucentis' global market was valued at $630 million in 2024 and is projected to reach $1.07 billion by 2031, reflecting a CAGR of 8% over the forecast period, with Genentech holding U.S. rights and Novartis commercializing ex-U.S. markets.
LUPIN has traded between INR 1,836.80 and INR 2,494 over the past year. The stock closed Thursday's trading at INR 2,249, down 0.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.